Welcome to Annexin's IR pages
Annexin Pharmaceuticals AB (publ) was founded in 2014 and is a world-leading biotechnology company in the Annexin A5 area, for the treatment of various diseases that involve damage and inflammation in the blood vessels.
IR contact:
Anders Haegerstrand, CEO
anders.haegerstrand@annexinpharma.com
Susanne Andersson, Chief Financial Officer
susanne.andersson@annexinpharma.com